Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAGMIN added to standard therapy in patients with lung cancer
2005-002438-37Phase 3Completed
- Sponsor
- Velindre University NHS Trust
- Start
- Nov 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dalteparin in bronchial carcinoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Velindre University NHS Trust. Primary endpoint: Overall survival. Started Nov 2006; status: completed.
02
Drugs
dalteparin
03
Conditions
bronchial carcinomasmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-002438-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002438-37.